Watchlist

Watchlist
Akari Therapeutics Plc (AKTX)
Akari Therapeutics Plc (AKTX)
Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)
This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXNs competition. I have previously reviewed a large number of ALXNs compet…
Achillion, Omeros, Ra Rx, Reata, Chemocentryx And Others In The IgA Nephropathy Space
I began this article with the intent of an Achillion Pharmaceuticals ( ACHN ) focus. However, as I learned more about each of these 5 companies, I've decided to give an equal spotlight to each. I will preface the real reason for this renal-focused article is due to my own diagnosis of IgA neph…
Akari Therapeutics' (AKTX) CEO David Solomon on Q4 2017 Results - Earnings Call Transcript
Akari Therapeutics, Inc. (AKTX) Q4 2017 Earnings Conference Call March 21, 2018, 08:30 ET Executives Peter Vozzo - West Wicke Partners David Solomon - CEO Dov Elefant - CFO Analysts Tim Lugo - William Blair Madhu Kumar - B. Riley FBR Presentation Operator Good m…
Akari Therapeutics reports Q4 results
Akari Therapeutics ( AKTX ) Q4 results : Revenues: $0; R&D Expense: $7.1M (+7.6%); SG&A: $3.7M (+12.1%); Operating Loss: ($10.8M) (-9.1%); Net Loss: ($9.3M) (-12.0%); Loss Per Share: ($0.01); Quick Assets: $28.1M (-36.3%). More news on: Akari Therapeutics Plc, Healthcare stocks ne…
Alexion's long-acting PNH candidate ALXN1210 on par with Soliris in late-stage study; shares up 11% premarket
Alexion Pharmaceuticals (NASDAQ: ALXN ) is up 11% premarket on light volume in response to its announcement of successful results from a Phase 3 clinical trial assessing ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria (PNH). More news on: Alexion Pharmaceuticals…
Alexion Ups Its Game With ALXN1210 SC
Alexion Pharmaceuticals ( ALXN ) a biopharmaceutical company which markets the blockbuster drug Soliris, is near the end of its journey to develop an even better version of Soliris called ALXN1210. Both Soliris (eculizumab) and ALXN1210 are antibodies which bind the complement protein C5, whic…
Premarket Gainers as of 9:05 am (02/06/2018)
ARGS +12% on option for group of PD-1 inhibitors. More news on: Argos Therapeutics, Inc., Akari Therapeutics Plc, Lumentum Holdings Inc., Stocks on the move, Read more …
Akari completes mid-stage study of Coversin in PNH; shares up 13% premarket
Thinly traded nano cap Akari Therapeutics (NASDAQ: AKTX ) is up 13% premarket on light volume in response to its announcement of final results from an eight-subject 90-day open-label Phase 2 clinical trial, COBALT, evaluating lead candidate Coversin in patients with paroxysmal …
Achillion Pharmaceuticals: Ultra-Rare Disease Company With Ultra-Rare Enterprise Value
Background of the Company Achillion ( ACHN ) is a biopharmaceutical company specializing in discovering and developing small molecules for complement-mediated diseases. The complement system is a part of the human innate immune system and is believed to comprise three pathways - the alt…
Apellis Pharmaceuticals: This Horse Is Lame
The approval of any drug by the FDA is based on the concept of benefit/risk. Obviously, for a drug to get approved, those knowledgeable in the field must believe that the benefits of the drug outweigh the risks. This benefit/risk ratio is a moving target. The risk that a patient would find acc…
Akari Therapeutics Plc (AKTX)